Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib

Podobne knjige/članki

• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
  od: Pao, William, et al.
  Izdano: (2005)
• Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations
  od: Janjigian, Yelena Y., et al.
  Izdano: (2011)
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  od: Pao, William, et al.
  Izdano: (2005)
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  od: Pao, William, et al.
  Izdano: (2004)
• Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib
  od: Johnson, Melissa L., et al.
  Izdano: (2011)